Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Z Rheumatol ; 79(6): 574-577, 2020 Aug.
Artículo en Alemán | MEDLINE | ID: covidwho-591323

RESUMEN

A case with rheumatoid arthritis and insufficient compensation under disease-modifying combined long-term therapy with methotrexate and leflunomide is reported. After recovery from a COVID-19 infection, a tumor necrosis factor (TNF) inhibitor therapy was initiated. Until now no reactivation of the COVID-19 infection with positive SARS-CoV­2 antibody status has occurred.


Asunto(s)
Anticuerpos Antivirales/sangre , Artritis Reumatoide/tratamiento farmacológico , Terapia Biológica , Infecciones por Coronavirus/complicaciones , Neumonía Viral/complicaciones , Artritis Reumatoide/virología , Betacoronavirus , COVID-19 , Humanos , Leflunamida/uso terapéutico , Metotrexato/uso terapéutico , Pandemias , SARS-CoV-2 , Inhibidores del Factor de Necrosis Tumoral/uso terapéutico , Activación Viral
2.
Z Rheumatol ; 79(4): 379-384, 2020 May.
Artículo en Alemán | MEDLINE | ID: covidwho-95158

RESUMEN

The current COVID-19 pandemic inherits an unprecedented challenge for the treating rheumatologists. On the one hand, antirheumatic drugs can increase the risk of infection and potentially deteriorate the course of an infection. On the other hand, an active inflammatory rheumatic disease can also increase the risk for an infection. In the recommendations of the German Society for Rheumatology (www.dgrh.de), it is recommended that our patients continue the antirheumatic therapy to maintain remission or low state of activity despite the pandemic. In this study, patients with inflammatory rheumatic disease were asked in the first weeks of the pandemic on their opinion of their immunomodulating therapy. The result shows that over 90% of the patients followed the recommendation of the rheumatologist to continue the antirheumatic therapy, and only a small percentage of the patients terminated the therapy on their own. This result was independent of the individual anti-rheumatic therapy. Taken together, the results of this study illustrate not only the trustful patient-physician partnership in a threatening situation but also the high impact of state-of-the art recommendations by the respective scientific society.


Asunto(s)
Infecciones por Coronavirus , Huésped Inmunocomprometido , Cumplimiento de la Medicación , Pandemias , Neumonía Viral , Enfermedades Reumáticas/inmunología , Antirreumáticos/efectos adversos , Antirreumáticos/uso terapéutico , Betacoronavirus , COVID-19 , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/inmunología , Estudios Transversales , Humanos , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Neumonía Viral/epidemiología , Neumonía Viral/inmunología , Enfermedades Reumáticas/complicaciones , Enfermedades Reumáticas/tratamiento farmacológico , SARS-CoV-2
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA